Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Testing av tillegg av Trastuzumab eller Trastuzumab/Pertuzumab til vanlig kjemoterapi for HER2-positivt endometrielt serøst karsinom eller karsinosarkom

1. oktober 2026 oppdatert av: National Cancer Institute (NCI)

En fase II/III-studie av paklitaxel/karboplatin alene eller kombinert med enten Trastuzumab og Hyaluronidase-Oysk (HERCEPTIN HYLECTA) eller Pertuzumab, Trastuzumab og Hyaluronidase-Zzxf (PHESGO) i HER2 Positivt, Stage I-IV-karcinometometrisk karcinometrometri

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta [TM]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo [TM]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) and pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) in combination with paclitaxel/carboplatin in patients with HER2 positive endometrial cancer.

II. To evaluate the overall response rate (ORR) in patients with measurable disease.

III. To evaluate the duration of objective response in patients with measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

IV. To determine the nature, frequency and degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0 for each treatment arm.

V. To compare quality of life (QOL), as measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En-TOI), in the experimental versus control arms.

VI. To compare patient-reported treatment-associated symptoms (diarrhea and rash) as measured with the Patient Reported Outcomes (PRO) - CTCAE, patient-reported fatigue as measured with the Patient Reported Outcomes Measurement Information System (PROMIS)-Fatigue short form, and worry concerning side effects of treatment as measured by the item 'bothered by side effect', in the FACT-En TOI, respectively, in the experimental and control arms.

VII. To assess the correlation of HER2 immunohistochemistry (IHC) expression and in situ hybridization (ISH) amplification with clinical outcome and response to HER2 targeted therapies.

EXPLORATORY OBJECTIVE:

I. To explore time to sustained deterioration in quality of life, as measured by a drop in the FACT-En-TOI by 6 or more points lasting for more than one PRO time point, in the experimental and control arms.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable disease (SD) or partial response (PR) who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.

ARM II: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk subcutaneously (SC) over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.

MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.

ARM III: Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and pertuzumab/trastuzumab/hyaluronidase-zzxf SC over 5-8 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.

MAINTENANCE: Patients receive pertuzumab/trastuzumab/ hyaluronidase-zzxf SC over 5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance for up to 3 years from the start of treatment.

Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) and computed tomography (CT) throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Studietype

Intervensjonell

Registrering (Antatt)

360

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • University of Alabama at Birmingham Cancer Center
    • Alaska
      • Anchorage, Alaska, Forente stater, 99508
        • Alaska Women's Cancer Care
    • Arizona
      • Tucson, Arizona, Forente stater, 85719
        • Banner University Medical Center - Tucson
      • Tucson, Arizona, Forente stater, 85719
        • University of Arizona Cancer Center-North Campus
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • University of Arkansas for Medical Sciences
    • California
      • Auburn, California, Forente stater, 95602
        • Sutter Auburn Faith Hospital
      • Berkeley, California, Forente stater, 94704
        • Alta Bates Summit Medical Center-Herrick Campus
      • Concord, California, Forente stater, 94520
        • John Muir Medical Center-Concord
      • Duarte, California, Forente stater, 91010
        • City of Hope Comprehensive Cancer Center
      • Huntington Beach, California, Forente stater, 92648
        • City of Hope Seacliff
      • Irvine, California, Forente stater, 92618
        • Kaiser Permanente-Irvine
      • Irvine, California, Forente stater, 92618
        • City of Hope at Irvine Lennar
      • Irvine, California, Forente stater, 92612
        • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
      • Long Beach, California, Forente stater, 90813
        • City of Hope at Long Beach Elm
      • Los Angeles, California, Forente stater, 90027
        • Kaiser Permanente Los Angeles Medical Center
      • Modesto, California, Forente stater, 95355
        • Memorial Medical Center
      • Mountain View, California, Forente stater, 94040
        • Palo Alto Medical Foundation-Gynecologic Oncology
      • Orange, California, Forente stater, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • Orange, California, Forente stater, 92868
        • Saint Joseph Hospital - Orange
      • Palo Alto, California, Forente stater, 94304
        • Stanford Cancer Institute Palo Alto
      • Panorama City, California, Forente stater, 91402
        • Kaiser Permanente - Panorama City
      • Riverside, California, Forente stater, 92505
        • Kaiser Permanente-Riverside
      • Roseville, California, Forente stater, 95661
        • Sutter Roseville Medical Center
      • Sacramento, California, Forente stater, 95816
        • Sutter Medical Center Sacramento
      • Sacramento, California, Forente stater, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Francisco, California, Forente stater, 94115
        • California Pacific Medical Center-Pacific Campus
      • Santa Cruz, California, Forente stater, 95065
        • Palo Alto Medical Foundation-Santa Cruz
      • Sunnyvale, California, Forente stater, 94086
        • Palo Alto Medical Foundation-Sunnyvale
      • Upland, California, Forente stater, 91786
        • City of Hope Upland
      • Walnut Creek, California, Forente stater, 94598
        • John Muir Medical Center-Walnut Creek
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • UCHealth University of Colorado Hospital
      • Denver, Colorado, Forente stater, 80206
        • UCHealth - Cherry Creek
      • Denver, Colorado, Forente stater, 80210
        • AdventHealth Porter
      • Grand Junction, Colorado, Forente stater, 81505
        • Grand Valley Oncology
      • Greeley, Colorado, Forente stater, 80631
        • Banner North Colorado Medical Center
      • Highlands Ranch, Colorado, Forente stater, 80129
        • UCHealth Highlands Ranch Hospital
      • Loveland, Colorado, Forente stater, 80539
        • Banner North Colorado Medical Center - Loveland Campus
    • Connecticut
      • Danbury, Connecticut, Forente stater, 06810
        • Danbury Hospital
      • Derby, Connecticut, Forente stater, 06418
        • Smilow Cancer Hospital-Derby Care Center
      • Fairfield, Connecticut, Forente stater, 06824
        • Smilow Cancer Hospital Care Center-Fairfield
      • Glastonbury, Connecticut, Forente stater, 06033
        • Smilow Cancer Hospital Care Center at Glastonbury
      • Greenwich, Connecticut, Forente stater, 06830
        • Smilow Cancer Hospital Care Center at Greenwich
      • Guilford, Connecticut, Forente stater, 06437
        • Smilow Cancer Hospital Care Center - Guilford
      • Hartford, Connecticut, Forente stater, 06105
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, Forente stater, 06520
        • Yale University
      • North Haven, Connecticut, Forente stater, 06473
        • Yale-New Haven Hospital North Haven Medical Center
      • Norwalk, Connecticut, Forente stater, 06856
        • Norwalk Hospital
      • Stamford, Connecticut, Forente stater, 06902
        • Smilow Cancer Hospital Care Center at Long Ridge
      • Torrington, Connecticut, Forente stater, 06790
        • Smilow Cancer Hospital-Torrington Care Center
      • Trumbull, Connecticut, Forente stater, 06611
        • Smilow Cancer Hospital Care Center-Trumbull
      • Waterbury, Connecticut, Forente stater, 06708
        • Smilow Cancer Hospital-Waterbury Care Center
      • Waterford, Connecticut, Forente stater, 06385
        • Smilow Cancer Hospital Care Center - Waterford
    • Delaware
      • Newark, Delaware, Forente stater, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Forente stater, 19713
        • Medical Oncology Hematology Consultants PA
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20037
        • George Washington University Medical Center
      • Washington D.C., District of Columbia, Forente stater, 20016
        • Sibley Memorial Hospital
    • Florida
      • Fort Lauderdale, Florida, Forente stater, 33316
        • Broward Health Medical Center
      • Jupiter, Florida, Forente stater, 33458
        • Jupiter Medical Center
      • N. Venice, Florida, Forente stater, 34275
        • Sarasota Memorial Hospital-Venice
      • Orlando, Florida, Forente stater, 32803
        • AdventHealth Orlando
      • Sarasota, Florida, Forente stater, 34239
        • Sarasota Memorial Hospital
      • Sarasota, Florida, Forente stater, 34239
        • Florida Cancer Specialists - Sarasota Downtown
      • Sarasota, Florida, Forente stater, 34239
        • FPG - Surgical Oncology Clinics Gynecologic Oncology Surgery
      • Venice, Florida, Forente stater, 34275
        • Florida Cancer Specialists - Venice Pinebrook
    • Georgia
      • Atlanta, Georgia, Forente stater, 30308
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Forente stater, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Forente stater, 30342
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Forente stater, 30303
        • Grady Health System
      • Atlanta, Georgia, Forente stater, 30309
        • Piedmont Hospital
      • Augusta, Georgia, Forente stater, 30912
        • Augusta University Medical Center
      • Decatur, Georgia, Forente stater, 30033
        • Emory Decatur Hospital
      • Savannah, Georgia, Forente stater, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu, Hawaii, Forente stater, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Forente stater, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Forente stater, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Boise, Idaho, Forente stater, 83712
        • Saint Luke's Cancer Institute - Boise
      • Caldwell, Idaho, Forente stater, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Forente stater, 83814
        • Kootenai Health - Coeur d'Alene
      • Fruitland, Idaho, Forente stater, 83619
        • Saint Luke's Cancer Institute - Fruitland
      • Meridian, Idaho, Forente stater, 83642
        • Saint Luke's Cancer Institute - Meridian
      • Nampa, Idaho, Forente stater, 83687
        • Saint Alphonsus Cancer Care Center-Nampa
      • Nampa, Idaho, Forente stater, 83687
        • Saint Luke's Cancer Institute - Nampa
      • Post Falls, Idaho, Forente stater, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Forente stater, 83864
        • Kootenai Clinic Cancer Services - Sandpoint
      • Twin Falls, Idaho, Forente stater, 83301
        • Saint Luke's Cancer Institute - Twin Falls
    • Illinois
      • Arlington Heights, Illinois, Forente stater, 60005
        • Northwest Community Hospital
      • Aurora, Illinois, Forente stater, 60504
        • Rush-Copley Medical Center
      • Centralia, Illinois, Forente stater, 62801
        • Centralia Oncology Clinic
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern University
      • Chicago, Illinois, Forente stater, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Forente stater, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Forente stater, 60612
        • Rush MD Anderson Cancer Center
      • Danville, Illinois, Forente stater, 61832
        • Carle at The Riverfront
      • DeKalb, Illinois, Forente stater, 60115
        • Northwestern Medicine Cancer Center Kishwaukee
      • Decatur, Illinois, Forente stater, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Forente stater, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham, Illinois, Forente stater, 62401
        • Crossroads Cancer Center
      • Effingham, Illinois, Forente stater, 62401
        • Carle Physician Group-Effingham
      • Evanston, Illinois, Forente stater, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Geneva, Illinois, Forente stater, 60134
        • Northwestern Medicine Cancer Center Delnor
      • Glenview, Illinois, Forente stater, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Glenview, Illinois, Forente stater, 60026
        • Northwestern Medicine Glenview Outpatient Center
      • Grayslake, Illinois, Forente stater, 60030
        • Northwestern Medicine Grayslake Outpatient Center
      • Harvey, Illinois, Forente stater, 60426
        • Ingalls Memorial Hospital
      • Highland Park, Illinois, Forente stater, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Hinsdale, Illinois, Forente stater, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Lake Forest, Illinois, Forente stater, 60045
        • Northwestern Medicine Lake Forest Hospital
      • Mattoon, Illinois, Forente stater, 61938
        • Carle Physician Group-Mattoon/Charleston
      • New Lenox, Illinois, Forente stater, 60451
        • UC Comprehensive Cancer Center at Silver Cross
      • Normal, Illinois, Forente stater, 61761
        • Carle Cancer Institute Normal
      • O'Fallon, Illinois, Forente stater, 62269
        • Cancer Care Center of O'Fallon
      • Orland Park, Illinois, Forente stater, 60462
        • University of Chicago Medicine-Orland Park
      • Orland Park, Illinois, Forente stater, 60462
        • Northwestern Medicine Orland Park
      • Rockford, Illinois, Forente stater, 61114
        • UW Health Carbone Cancer Center Rockford
      • Springfield, Illinois, Forente stater, 62702
        • Southern Illinois University School of Medicine
      • Springfield, Illinois, Forente stater, 62702
        • Springfield Clinic
      • Springfield, Illinois, Forente stater, 62781
        • Springfield Memorial Hospital
      • Urbana, Illinois, Forente stater, 61801
        • Carle Cancer Center
      • Warrenville, Illinois, Forente stater, 60555
        • Northwestern Medicine Cancer Center Warrenville
      • Yorkville, Illinois, Forente stater, 60560
        • Rush-Copley Healthcare Center
    • Indiana
      • Carmel, Indiana, Forente stater, 46032
        • IU Health North Hospital
      • Crown Point, Indiana, Forente stater, 46307
        • UChicago Medicine Northwest Indiana
      • Crown Point, Indiana, Forente stater, 46307
        • Northwest Cancer Center - Crown Point
      • Dyer, Indiana, Forente stater, 46311
        • Northwest Oncology LLC
      • Goshen, Indiana, Forente stater, 46526
        • Goshen Center for Cancer Care
      • Hobart, Indiana, Forente stater, 46342
        • Northwest Cancer Center - Hobart
      • Hobart, Indiana, Forente stater, 46342
        • Saint Mary Medical Center
      • Indianapolis, Indiana, Forente stater, 46237
        • Franciscan Health Indianapolis
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Forente stater, 46260
        • Ascension Saint Vincent Indianapolis Hospital
      • Indianapolis, Indiana, Forente stater, 46312
        • Saint Catherine Hospital
      • Lafayette, Indiana, Forente stater, 47905
        • Franciscan Saint Elizabeth Health - Lafayette East
      • Mooresville, Indiana, Forente stater, 46158
        • Franciscan Health Mooresville
      • Munster, Indiana, Forente stater, 46321
        • The Community Hospital
      • Munster, Indiana, Forente stater, 46321
        • Women's Diagnostic Center - Munster
      • South Bend, Indiana, Forente stater, 46601
        • Memorial Hospital of South Bend
      • Valparaiso, Indiana, Forente stater, 46383
        • Northwest Cancer Center - Valparaiso
    • Iowa
      • Ames, Iowa, Forente stater, 50010
        • Mary Greeley Medical Center
      • Ames, Iowa, Forente stater, 50010
        • McFarland Clinic - Ames
      • Boone, Iowa, Forente stater, 50036
        • McFarland Clinic - Boone
      • Council Bluffs, Iowa, Forente stater, 51503
        • Heartland Oncology and Hematology LLP
      • Council Bluffs, Iowa, Forente stater, 51503
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
      • Fort Dodge, Iowa, Forente stater, 50501
        • McFarland Clinic - Trinity Cancer Center
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
      • Jefferson, Iowa, Forente stater, 50129
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Forente stater, 50158
        • McFarland Clinic - Marshalltown
    • Kansas
      • Shawnee Mission, Kansas, Forente stater, 66204
        • AdventHealth Shawnee Mission
    • Kentucky
      • Edgewood, Kentucky, Forente stater, 41017
        • Saint Elizabeth Healthcare Edgewood
      • Lexington, Kentucky, Forente stater, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, Forente stater, 40207
        • Baptist Health Louisville
    • Louisiana
      • Baton Rouge, Louisiana, Forente stater, 70805
        • LSU Health Baton Rouge-North Clinic
      • Baton Rouge, Louisiana, Forente stater, 70817
        • Our Lady of the Lake Medical Oncology
      • Baton Rouge, Louisiana, Forente stater, 70808
        • Our Lady of the Lake Physician Group
      • Covington, Louisiana, Forente stater, 70433
        • Ochsner Hematology Oncology North Shore - Covington (West Region)
      • Marrero, Louisiana, Forente stater, 70072
        • West Jefferson Medical Center
      • Metairie, Louisiana, Forente stater, 70006
        • East Jefferson General Hospital
      • Metairie, Louisiana, Forente stater, 70006
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
      • New Orleans, Louisiana, Forente stater, 70121
        • Ochsner Medical Center Jefferson
      • New Orleans, Louisiana, Forente stater, 70112
        • University Medical Center New Orleans
      • New Orleans, Louisiana, Forente stater, 70115
        • Ochsner Baptist Medical Center
    • Maine
      • Augusta, Maine, Forente stater, 04330
        • Harold Alfond Center for Cancer Care
      • Scarborough, Maine, Forente stater, 04074
        • MaineHealth Maine Medical Center- Scarborough
    • Maryland
      • Baltimore, Maryland, Forente stater, 21237
        • MedStar Franklin Square Medical Center/Weinberg Cancer Institute
      • Baltimore, Maryland, Forente stater, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Forente stater, 21215
        • Sinai Hospital of Baltimore
      • Baltimore, Maryland, Forente stater, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, Forente stater, 20889-5600
        • Walter Reed National Military Medical Center
      • Westminster, Maryland, Forente stater, 21157
        • William E Kahlert Regional Cancer Center/Sinai Hospital
    • Massachusetts
      • Springfield, Massachusetts, Forente stater, 01199
        • Baystate Medical Center
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan Rogel Cancer Center
      • Battle Creek, Michigan, Forente stater, 49017
        • Bronson Battle Creek
      • Brighton, Michigan, Forente stater, 48114
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
      • Canton, Michigan, Forente stater, 48188
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
      • Chelsea, Michigan, Forente stater, 48118
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
      • Detroit, Michigan, Forente stater, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills, Michigan, Forente stater, 48334
        • Weisberg Cancer Treatment Center
      • Farmington Hills, Michigan, Forente stater, 48336
        • Corewell Health Farmington Hills Hospital
      • Flint, Michigan, Forente stater, 48503
        • Hurley Medical Center
      • Flint, Michigan, Forente stater, 48503
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Forente stater, 48503
        • Genesys Hurley Cancer Institute
      • Flint, Michigan, Forente stater, 48503
        • Cancer Hematology Centers - Flint
      • Grand Rapids, Michigan, Forente stater, 49503
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Forente stater, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Kalamazoo, Michigan, Forente stater, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Forente stater, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, Forente stater, 49009
        • Beacon Kalamazoo Cancer Center
      • Lansing, Michigan, Forente stater, 48912
        • University of Michigan Health - Sparrow Lansing
      • Livonia, Michigan, Forente stater, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Muskegon, Michigan, Forente stater, 49444
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Forente stater, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Forente stater, 49444
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Pontiac, Michigan, Forente stater, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
      • Reed City, Michigan, Forente stater, 49677
        • Corewell Health Reed City Hospital
      • Royal Oak, Michigan, Forente stater, 48073
        • Corewell Health William Beaumont University Hospital
      • Saginaw, Michigan, Forente stater, 48604
        • Oncology Hematology Associates of Saginaw Valley PC
      • Saginaw, Michigan, Forente stater, 48601
        • MyMichigan Medical Center Saginaw
      • Saint Joseph, Michigan, Forente stater, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Forente stater, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Tawas City, Michigan, Forente stater, 48764
        • MyMichigan Medical Center Tawas
      • Traverse City, Michigan, Forente stater, 49684
        • Munson Medical Center
      • Troy, Michigan, Forente stater, 48085
        • Corewell Health Beaumont Troy Hospital
      • West Branch, Michigan, Forente stater, 48661
        • Saint Mary's Oncology/Hematology Associates of West Branch
      • Wyoming, Michigan, Forente stater, 49519
        • University of Michigan Health - West
      • Ypsilanti, Michigan, Forente stater, 48197
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
    • Minnesota
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Mercy Hospital
      • Edina, Minnesota, Forente stater, 55435
        • Fairview Southdale Hospital
      • Edina, Minnesota, Forente stater, 55435
        • Minnesota Oncology - Edina
      • Maplewood, Minnesota, Forente stater, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Marshall, Minnesota, Forente stater, 56258
        • Avera Cancer Institute at Marshall
      • Minneapolis, Minnesota, Forente stater, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota/Masonic Cancer Center
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Paul, Minnesota, Forente stater, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Forente stater, 55102
        • United Hospital
      • Woodbury, Minnesota, Forente stater, 55125
        • Minnesota Oncology Hematology PA-Woodbury
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • MU Health - University Hospital/Ellis Fischel Cancer Center
      • Rolla, Missouri, Forente stater, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Springfield, Missouri, Forente stater, 65807
        • CoxHealth South Hospital
      • St Louis, Missouri, Forente stater, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Forente stater, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Forente stater, 63128
        • Mercy Hospital South
    • Montana
      • Anaconda, Montana, Forente stater, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Forente stater, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Forente stater, 59102
        • Saint Vincent Frontier Cancer Center
      • Billings, Montana, Forente stater, 59106
        • Intermountain Health West End Clinic
      • Bozeman, Montana, Forente stater, 59715
        • Bozeman Health Deaconess Hospital
      • Great Falls, Montana, Forente stater, 59405
        • Benefis Sletten Cancer Institute
      • Kalispell, Montana, Forente stater, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Forente stater, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Forente stater, 59804
        • Community Medical Center
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68114
        • Nebraska Methodist Hospital
      • Omaha, Nebraska, Forente stater, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Forente stater, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Forente stater, 68114
        • Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Forente stater, 89106
        • Women's Cancer Center of Nevada
      • Las Vegas, Nevada, Forente stater, 89183
        • OptumCare Cancer Care at Fort Apache
    • New Jersey
      • Basking Ridge, New Jersey, Forente stater, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Camden, New Jersey, Forente stater, 08103
        • Cooper Hospital University Medical Center
      • Hackensack, New Jersey, Forente stater, 07601
        • Hackensack University Medical Center
      • Lakewood, New Jersey, Forente stater, 08701
        • Monmouth Medical Center Southern Campus
      • Livingston, New Jersey, Forente stater, 07039
        • Cooperman Barnabas Medical Center
      • Long Branch, New Jersey, Forente stater, 07740
        • Monmouth Medical Center
      • Middletown, New Jersey, Forente stater, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, Forente stater, 07645
        • Memorial Sloan Kettering Bergen
      • Moorestown, New Jersey, Forente stater, 08057
        • Virtua Samson Cancer Center
      • Neptune City, New Jersey, Forente stater, 07753
        • Jersey Shore Medical Center
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rutgers Cancer Institute of New Jersey
      • Newark, New Jersey, Forente stater, 07101
        • Rutgers New Jersey Medical School
      • Red Bank, New Jersey, Forente stater, 07701
        • Riverview Medical Center/Booker Cancer Center
      • Sewell, New Jersey, Forente stater, 08080
        • Sidney Kimmel Cancer Center Washington Township
      • Somerville, New Jersey, Forente stater, 08876
        • Robert Wood Johnson University Hospital Somerset
      • Toms River, New Jersey, Forente stater, 08755
        • Community Medical Center
      • Voorhees Township, New Jersey, Forente stater, 08043
        • Virtua Voorhees
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • University of New Mexico Cancer Center
      • Albuquerque, New Mexico, Forente stater, 87110
        • Presbyterian Kaseman Hospital
      • Rio Rancho, New Mexico, Forente stater, 87124
        • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    • New York
      • Albany, New York, Forente stater, 12208
        • Women's Cancer Care Associates LLC
      • Commack, New York, Forente stater, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, Forente stater, 10604
        • Memorial Sloan Kettering Westchester
      • Mineola, New York, Forente stater, 11501
        • NYU Langone Hospital - Long Island
      • New York, New York, Forente stater, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Forente stater, 10029
        • Mount Sinai Hospital
      • New York, New York, Forente stater, 10011
        • Mount Sinai Chelsea
      • New York, New York, Forente stater, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, Forente stater, 14642
        • University of Rochester
      • Syracuse, New York, Forente stater, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Forente stater, 10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx, New York, Forente stater, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, Forente stater, 10461
        • Montefiore Medical Center-Weiler Hospital
      • Uniondale, New York, Forente stater, 11553
        • Memorial Sloan Kettering Nassau
      • Webster, New York, Forente stater, 14580
        • Wilmot Cancer Institute at Webster
    • North Carolina
      • Cary, North Carolina, Forente stater, 27518
        • Duke Cancer Center Cary
      • Chapel Hill, North Carolina, Forente stater, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Durham, North Carolina, Forente stater, 27710
        • Duke University Medical Center
      • Greenville, North Carolina, Forente stater, 27834
        • ECU Health Medical Center
      • High Point, North Carolina, Forente stater, 27262
        • Hayworth Cancer Center
      • Raleigh, North Carolina, Forente stater, 27607
        • Duke Women's Cancer Care Raleigh
      • Wilmington, North Carolina, Forente stater, 28401
        • Novant Health New Hanover Regional Medical Center
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Bismarck, North Dakota, Forente stater, 58501
        • Sanford Bismarck Medical Center
      • Fargo, North Dakota, Forente stater, 58122
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Forente stater, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Beachwood, Ohio, Forente stater, 44122
        • UHHS-Chagrin Highlands Medical Center
      • Belpre, Ohio, Forente stater, 45714
        • Strecker Cancer Center-Belpre
      • Canton, Ohio, Forente stater, 44710
        • Aultman Health Foundation
      • Centerville, Ohio, Forente stater, 45459
        • Miami Valley Hospital South
      • Chardon, Ohio, Forente stater, 44024
        • Geauga Hospital
      • Chillicothe, Ohio, Forente stater, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Forente stater, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cleveland, Ohio, Forente stater, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Forente stater, 44109
        • MetroHealth Medical Center
      • Columbus, Ohio, Forente stater, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Forente stater, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Forente stater, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Forente stater, 43213
        • Mount Carmel East Hospital
      • Dayton, Ohio, Forente stater, 45409
        • Miami Valley Hospital
      • Dayton, Ohio, Forente stater, 45415
        • Miami Valley Hospital North
      • Franklin, Ohio, Forente stater, 45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Greenville, Ohio, Forente stater, 45331
        • Miami Valley Cancer Care and Infusion
      • Grove City, Ohio, Forente stater, 43123
        • Mount Carmel Grove City Hospital
      • Lancaster, Ohio, Forente stater, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Forente stater, 45801
        • Saint Rita's Medical Center
      • Marietta, Ohio, Forente stater, 45750
        • Marietta Memorial Hospital
      • Marysville, Ohio, Forente stater, 43040
        • Memorial Hospital
      • Mentor, Ohio, Forente stater, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, Forente stater, 43050
        • Knox Community Hospital
      • Newark, Ohio, Forente stater, 43055
        • Licking Memorial Hospital
      • Parma, Ohio, Forente stater, 44129
        • University Hospitals Parma Medical Center
      • Perrysburg, Ohio, Forente stater, 43551
        • Mercy Health - Perrysburg Hospital
      • Portsmouth, Ohio, Forente stater, 45662
        • Southern Ohio Medical Center
      • Springfield, Ohio, Forente stater, 45504
        • Springfield Regional Cancer Center
      • Springfield, Ohio, Forente stater, 45504
        • Springfield Regional Medical Center
      • Sylvania, Ohio, Forente stater, 43560
        • ProMedica Flower Hospital
      • Toledo, Ohio, Forente stater, 43623
        • Mercy Health - Saint Anne Hospital
      • Toledo, Ohio, Forente stater, 43608
        • Mercy Health - Saint Vincent Hospital
      • Troy, Ohio, Forente stater, 45373
        • Upper Valley Medical Center
      • Westerville, Ohio, Forente stater, 43081
        • Saint Ann's Hospital
      • Westlake, Ohio, Forente stater, 44145
        • UH Seidman Cancer Center at Saint John Medical Center
      • Zanesville, Ohio, Forente stater, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • University of Oklahoma Health Sciences Center
      • Oklahoma City, Oklahoma, Forente stater, 73120
        • Mercy Hospital Oklahoma City
      • Tulsa, Oklahoma, Forente stater, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Clackamas, Oregon, Forente stater, 97015
        • Providence Cancer Institute Clackamas Clinic
      • Newberg, Oregon, Forente stater, 97132
        • Providence Newberg Medical Center
      • Ontario, Oregon, Forente stater, 97914
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Forente stater, 97210
        • Legacy Good Samaritan Hospital and Medical Center
      • Portland, Oregon, Forente stater, 97213
        • Providence Portland Medical Center
      • Portland, Oregon, Forente stater, 97225
        • Providence Saint Vincent Medical Center
      • Tualatin, Oregon, Forente stater, 97062
        • Legacy Meridian Park Hospital
    • Pennsylvania
      • Allentown, Pennsylvania, Forente stater, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Allentown, Pennsylvania, Forente stater, 18104
        • Saint Luke's Cancer Center - Allentown
      • Bethlehem, Pennsylvania, Forente stater, 18017
        • Lehigh Valley Hospital - Muhlenberg
      • Bethlehem, Pennsylvania, Forente stater, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Bryn Mawr, Pennsylvania, Forente stater, 19010
        • Bryn Mawr Hospital
      • East Stroudsburg, Pennsylvania, Forente stater, 18301
        • Pocono Medical Center
      • Easton, Pennsylvania, Forente stater, 18045
        • Saint Luke's Hospital-Anderson Campus
      • Erie, Pennsylvania, Forente stater, 16544
        • Saint Vincent Hospital
      • Hazleton, Pennsylvania, Forente stater, 18201
        • Lehigh Valley Hospital-Hazleton
      • Jefferson Hills, Pennsylvania, Forente stater, 15025
        • Jefferson Hospital
      • Media, Pennsylvania, Forente stater, 19063
        • Riddle Memorial Hospital
      • Monroeville, Pennsylvania, Forente stater, 15146
        • Forbes Hospital
      • Paoli, Pennsylvania, Forente stater, 19301
        • Paoli Memorial Hospital
      • Philadelphia, Pennsylvania, Forente stater, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Pennsylvania Hospital
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • West Penn Hospital
      • Quakertown, Pennsylvania, Forente stater, 18951
        • Saint Luke's Hospital - Upper Bucks Campus
      • West Chester, Pennsylvania, Forente stater, 19380
        • Chester County Hospital
      • Wexford, Pennsylvania, Forente stater, 15090
        • Wexford Health and Wellness Pavilion
      • Willow Grove, Pennsylvania, Forente stater, 19090
        • Asplundh Cancer Pavilion
      • Wynnewood, Pennsylvania, Forente stater, 19096
        • Lankenau Medical Center
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02905
        • Women and Infants Hospital
      • Westerly, Rhode Island, Forente stater, 02891
        • Smilow Cancer Hospital Care Center - Westerly
    • South Carolina
      • Bluffton, South Carolina, Forente stater, 29910
        • Saint Joseph's/Candler - Bluffton Campus
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina
    • South Dakota
      • Aberdeen, South Dakota, Forente stater, 57401
        • Avera Cancer Institute-Aberdeen
      • Rapid City, South Dakota, Forente stater, 57701
        • Rapid City Regional Hospital
      • Sioux Falls, South Dakota, Forente stater, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Forente stater, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Forente stater, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Germantown, Tennessee, Forente stater, 38138
        • The West Clinic - Wolf River
    • Texas
      • Austin, Texas, Forente stater, 78712
        • University of Texas at Austin
      • Austin, Texas, Forente stater, 78701
        • Dell Seton Medical Center at The University of Texas
      • Dallas, Texas, Forente stater, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Forente stater, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Fort Worth, Texas, Forente stater, 76104
        • UT Southwestern/Simmons Cancer Center-Fort Worth
      • Fort Worth, Texas, Forente stater, 76104
        • Tarrant County Hospital District/JPS Health Network
      • Houston, Texas, Forente stater, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Forente stater, 77030
        • Memorial Hermann Texas Medical Center
      • Houston, Texas, Forente stater, 77070
        • Methodist Willowbrook Hospital
      • Houston, Texas, Forente stater, 77094
        • Houston Methodist West Hospital
      • Nassau Bay, Texas, Forente stater, 77058
        • Houston Methodist Saint John Hospital
      • Richardson, Texas, Forente stater, 75080
        • UT Southwestern Clinical Center at Richardson/Plano
      • Sugar Land, Texas, Forente stater, 77479
        • Houston Methodist Sugar Land Hospital
      • The Woodlands, Texas, Forente stater, 77385
        • Houston Methodist The Woodlands Hospital
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Huntsman Cancer Institute/University of Utah
      • South Jordan, Utah, Forente stater, 84009
        • South Jordan Health Center
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
        • University of Virginia Cancer Center
      • Richmond, Virginia, Forente stater, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Forente stater, 23229
        • Henrico Doctor's Hospital
      • Richmond, Virginia, Forente stater, 23298
        • VCU Massey Comprehensive Cancer Center
      • Roanoke, Virginia, Forente stater, 24033
        • Carilion Roanoke Memorial Hospital
    • Washington
      • Edmonds, Washington, Forente stater, 98026
        • Swedish Cancer Institute-Edmonds
      • Seattle, Washington, Forente stater, 98122
        • Swedish Medical Center-First Hill
      • Vancouver, Washington, Forente stater, 98686
        • Legacy Salmon Creek Hospital
    • West Virginia
      • Charleston, West Virginia, Forente stater, 25304
        • Vandalia Health/CAMC Institute for Academic Medicine
      • Morgantown, West Virginia, Forente stater, 26506
        • West Virginia University Healthcare
    • Wisconsin
      • Eau Claire, Wisconsin, Forente stater, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Green Bay, Wisconsin, Forente stater, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, Forente stater, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • La Crosse, Wisconsin, Forente stater, 54601
        • Gundersen Lutheran Medical Center
      • Madison, Wisconsin, Forente stater, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Madison, Wisconsin, Forente stater, 53718
        • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
      • Marshfield, Wisconsin, Forente stater, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Medical College of Wisconsin
      • Minocqua, Wisconsin, Forente stater, 54548
        • Marshfield Medical Center - Minocqua
      • Mukwonago, Wisconsin, Forente stater, 53149
        • ProHealth D N Greenwald Center
      • New Richmond, Wisconsin, Forente stater, 54017
        • Cancer Center of Western Wisconsin
      • Oconomowoc, Wisconsin, Forente stater, 53066
        • ProHealth Oconomowoc Memorial Hospital
      • Oconto Falls, Wisconsin, Forente stater, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Rice Lake, Wisconsin, Forente stater, 54868
        • Marshfield Medical Center-Rice Lake
      • Sheboygan, Wisconsin, Forente stater, 53081
        • Saint Vincent Hospital Cancer Center at Sheboygan
      • Sheboygan, Wisconsin, Forente stater, 53081
        • Sheboygan Physicians Group
      • Stevens Point, Wisconsin, Forente stater, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Sturgeon Bay, Wisconsin, Forente stater, 54235-1495
        • Saint Vincent Hospital Cancer Center at Sturgeon Bay
      • Waukesha, Wisconsin, Forente stater, 53188
        • UW Cancer Center at ProHealth Care
      • Weston, Wisconsin, Forente stater, 54476
        • Marshfield Medical Center - Weston
  • Puerto Rico
      • San Juan, Puerto Rico, 00927
        • Centro Comprensivo de Cancer de UPR
  • Sør -Korea
      • Seoul, Sør -Korea, 06273
        • Gangnam Severance Hospital
    • Daegu
      • Dalseo-gu, Daegu, Sør -Korea, 42601
        • Keimyung University-Dongsan Medical Center
    • Gyeongsangnam-do
      • Seoul, Gyeongsangnam-do, Sør -Korea, 51353
        • Samsung Changwon Hospital
    • Kyeonggi-do
      • Seongnam, Kyeonggi-do, Sør -Korea, 463-707
        • Seoul National University Bundang Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA-IVB, non-recurrent, chemotherapy (chemo)-naive, HER2-positive endometrial cancer. The following endometrial cancer types are eligible:

    • Serous

    • Other endometrial cancers (including clear cell, endometrioid, mixed epithelial, dedifferentiated/undifferentiated)

    • Carcinosarcoma

      • NOTE: Endometrial cancers that are mismatch repair deficient (dMMR) by IHC are not eligible

  • Histologic confirmation of the original primary tumor is required. Submission of surgical pathology report (or endometrial biopsy pathology report in patients who never undergo hysterectomy) is required

  • Patients must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration

  • Patients may have measurable disease, non-measurable disease, or no measurable disease. In patients with measurable disease, lesions will be defined and monitored by RECIST v 1.1. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by CT or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

  • For patients with uterine-confined (stage I) disease, the tumor must be invasive into the myometrium. Any amount of myoinvasion is acceptable for eligibility. Patients with non-invasive disease, endometrial intraepithelial carcinoma alone, or disease confined to a polyp will be excluded

  • All patients must have tumors that are HER2 positive as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 Breast Cancer guidelines. IHC and ISH testing will be done locally, at each participating institution and interpreted by local pathologists. In general HER2 positivity is defined as any of the following:

    • 3+ immunohistochemistry (IHC),
    • 2+ IHC with positive in situ hybridization (ISH) Alternatively, patients could be eligible if next generation sequencing (NGS) demonstrates HER2 (ERBB2) amplification. NGS testing can be performed through any designated labs as per the National Cancer Institute (NCI) MATCH/NCI Combo-MATCH trial.

Pathology report showing results of institutional HER2 testing (or NGS testing results) must be submitted.

Sites must submit all results available (IHC, ISH, and NGS)

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

  • Age >= 18

  • Platelets >= 100,000/mcl (within 14 days prior to registration)

  • Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration)

  • Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN) or estimated Glomerular filtration rate (eGFR) >= 50 mL/min using either the Cockcroft-Gault equation, the Modification of Diet in Renal Disease Study, or as reported in the comprehensive metabolic panel/basic metabolic panel (eGFR) (within 14 days prior to registration)

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (within 14 days prior to registration)

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial

  • Although the uterus will have been removed in the vast majority of patients, for patients of child-bearing potential: negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Patients will be considered of non-reproductive potential if they are either:

    • Postmenopausal (defined as at least 12 months with no menses without an alternative medical cause; in women < 45 years of age, a high follicle stimulating hormone [FSH] level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. In the absence of 12 months of amenorrhea, a single FSH measurement is insufficient); OR
    • Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to registration
    • Have a congenital or acquired condition that prevents childbearing

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria:

  • Prior Therapy:

    • Patients must NOT have received prior chemotherapy, biologic therapy, or targeted therapy for treatment of endometrial carcinoma

    • Patients must NOT have received prior radiation therapy for treatment of endometrial carcinoma. Prior radiation includes external beam pelvic radiation therapy, external beam extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy

      • NOTE: Vaginal brachytherapy for treatment of endometrial cancer is permitted during study treatment. Planned use of vaginal brachytherapy must be declared at time of registration

    • Patients may have received prior hormonal therapy for treatment of endometrial carcinoma. All hormonal therapy must be discontinued at least one week prior to registration

  • Patients may not have a planned interval cytoreduction or hysterectomy, prior to documentation of progression, after study registration

  • Patients may not have planned external beam radiotherapy, prior to documentation of progression, after study registration

  • Significant cardiovascular disease including:

    • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg despite antihypertensive medications
    • Myocardial infarction or unstable angina within 6 months prior to registration
    • New York Heart Association functional classification II, III or IV
    • Serious cardiac arrhythmia requiring medication. This does not include asymptomatic, atrial fibrillation with controlled ventricular rate

  • Significant lung disease: dyspnea at rest grade 2 or greater (resulting from extensive tumor involvement or other causes), pneumonitis grade 2 or greater, interstitial lung disease grade 2 or greater, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)

  • Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), uncontrolled interstitial lung disease, symptomatic congestive heart failure, or psychiatric illness/social situations that would limit compliance with study requirements

  • Treatment with strong CYP2C8 or CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to registration

  • Women who are unwilling to discontinue nursing

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Arm I (paclitaxel, carboplatin)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.

Patients undergo ECHO or MUGA and CT throughout the study. Additionally, patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
Legemiddel: Carboplatin

Given IV

Andre navn:
  • Blastokarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Karbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Platinwas
  • Ribocarbo
  • JM8
Legemiddel: Paclitaxel

Given IV

Andre navn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Fremgangsmåte: Computed Tomography

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype
Fremgangsmåte: Echocardiography Test

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC
Fremgangsmåte: Multigated Acquisition Scan

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
Fremgangsmåte: Biospecimen Collection

Undergo blood and urine sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Stråling: High-Dose-Rate Vaginal Cuff Brachytherapy

Undergo vaginal brachytherapy

Andre navn:
  • HDR-VCB
Eksperimentell: Arm II (paclitaxel, carboplatin, Herceptin Hylecta)

Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30-60 minutes, and trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with SD or PR who still have measurable disease after completion of cycle 6 may receive 4 additional cycles of this treatment at the discretion of the treating physician.

MAINTENANCE: Patients receive trastuzumab/hyaluronidase-oysk SC over 2-5 minutes on day 1 of each cycle. Cycles repeat every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients with SD or PR may continue maintenance therapy for up to 3 years from the start of treatment.

Patients undergo ECHO or MUGA and CT throughout the study. Additionally patients may optionally undergo blood sample collection throughout the study, vaginal brachytherapy on study, and urine sample collection prior to treatment.
Legemiddel: Carboplatin

Given IV

Andre navn:
  • Blastokarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Karbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Platinwas
  • Ribocarbo
  • JM8
Legemiddel: Paclitaxel

Given IV

Andre navn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Fremgangsmåte: Computed Tomography

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype
Fremgangsmåte: Echocardiography Test

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC
Fremgangsmåte: Multigated Acquisition Scan

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
Fremgangsmåte: Biospecimen Collection

Undergo blood and urine sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Stråling: High-Dose-Rate Vaginal Cuff Brachytherapy

Undergo vaginal brachytherapy

Andre navn:
  • HDR-VCB
Annen: Survey Administration

Ancillary studies

Legemiddel: Trastuzumab/Hyaluronidase-oysk

Given SC

Andre navn:
  • Herceptin Hylecta
  • Trastuzumab og Hyaluronidase-oysk
  • Trastuzumab og rekombinant human hyaluronidase PH20
  • Trastuzumab og rHuPH20
  • Trastuzumab-Hyaluronidase-oysk
  • Trastuzumab og Hyaluronidase
Eksperimentell: Arm III (paclitaxel, carboplatin, Phesgo)

See Detailed Description.
Legemiddel: Carboplatin

Given IV

Andre navn:
  • Blastokarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Karbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Platinwas
  • Ribocarbo
  • JM8
Legemiddel: Paclitaxel

Given IV

Andre navn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat
Fremgangsmåte: Computed Tomography

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype
Fremgangsmåte: Echocardiography Test

Undergo ECHO

Andre navn:
  • Ekkokardiografi
  • EC
Fremgangsmåte: Multigated Acquisition Scan

Undergo MUGA

Andre navn:
  • Skanning av blodbasseng
  • Likevektsradionuklidangiografi
  • Gated Blood Pool Imaging
  • MUGA
  • Radionuklid ventrikulografi
  • RNVG
  • SYMA-skanning
  • Synchronized Multigated Acquisition Scanning
Fremgangsmåte: Biospecimen Collection

Undergo blood and urine sample collection

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Stråling: High-Dose-Rate Vaginal Cuff Brachytherapy

Undergo vaginal brachytherapy

Andre navn:
  • HDR-VCB
Annen: Survey Administration

Ancillary studies

Legemiddel: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab

Given SC

Andre navn:
  • Pertuzumab, Trastuzumab og Hyaluronidase-zzxf
  • Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
  • Phesgo
  • Pertuzumab og Trastuzumab hyaluronidase

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression free survival
Tidsramme: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization

At the end of Phase 2 analysis, if both experimental arms demonstrate superiority to the reference, the experimental arms will be compared to each other.
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years from randomization
Overall survival
Tidsramme: From study entry to time of death or the date of last contact, assessed up to 5 years from randomization

If both experimental arms demonstrate superiority to the reference arm, the experimental arms will be compared to each other.
From study entry to time of death or the date of last contact, assessed up to 5 years from randomization
Incidence of dose limiting toxicities
Tidsramme: Up to end of cycle 3 (week 12)

A dose limiting toxicity is any treatment-related adverse event requiring permanent discontinuation of the experimental therapy prior to the completion of treatment cycle 3.
Up to end of cycle 3 (week 12)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective response rate (ORR)
Tidsramme: Within 12 months of initiating maintenance therapy

Defined as the binomial proportion of evaluable patients with a best overall response of complete response or partial response (by Response Evaluation Criteria in Solid Tumors 1.1) within 12 months of initiating maintenance therapy. Responses reported by the treating physician will be used for these analyses. The ORR estimates by treatment arm will be supported by their 2-sided, 95% Wilson-Score confidence intervals (Wilson, 1927; Agresti, 1998). The relative odds of response in each experimental group (versus [vs] the reference group) will be estimated using a multivariable logistic regression model specified with main effects for the treatment groups and covariate adjustments for the stratification factors reported at baseline.
Within 12 months of initiating maintenance therapy
Duration of objective response
Tidsramme: From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization

Treatment group differences in response duration will be graphed using Kaplan-Meier methods and compared using logrank tests, stratified by the minimization factors defined at randomization. The relative hazards of progression or death in each experimental group (vs the reference group) will be estimated using a multivariable proportional hazards regression model specified with main effects for the treatment indicators and covariate adjustments for the stratification factors reported at baseline.
From documentation of either partial response or complete response until disease progression or death, whichever is observed first, assessed up to 5 years from randomization
Incidence of adverse events (AEs)
Tidsramme: Up to 5 years from randomization

The nature, frequency, and degree of toxicity will be tabulated at the System Organ Class and AE-specific term levels using Common Terminology Criteria version 5.0. Each patient will be represented according to the maximum grade observed for each term. Tabulations will show the number and percentage of patients by maximum grade, within the treatment group received, regardless of the randomized treatment assignment.
Up to 5 years from randomization
HER2 expression
Tidsramme: Up to 5 years from randomization

Correlation of HER2 immunohistochemistry expression and in situ hybridization amplification with clinical outcome and response to HER2 targeted therapies will be explored.
Up to 5 years from randomization
Quality of life (QoL)
Tidsramme: Up to 5 years from randomization

Measured by Functional Assessment of Cancer Therapy - Endometrial Trial Outcome Index (FACT-En TOI).
Up to 5 years from randomization

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
QoL deterioration
Tidsramme: Baseline up to 5 years

The deterioration in QoL will be measured by a drop of >= 6 points in the FACT-En TOI score from baseline and lasting for more than one patient reported outcome time point in experimental and control arms.
Baseline up to 5 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

National Cancer Institute (NCI)

Samarbeidspartnere

NRG Oncology

Etterforskere

  • Hovedetterforsker: Britt K Erickson, NRG Oncology

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. november 2022

Primær fullføring (Antatt)

31. oktober 2027

Studiet fullført (Antatt)

31. oktober 2027

Datoer for studieregistrering

Først innsendt

24. februar 2022

Først innsendt som oppfylte QC-kriteriene

24. februar 2022

Først lagt ut (Faktiske)

25. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

1. oktober 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • NCI-2022-01540
  • U10CA180868 (U.S. NIH-stipend/kontrakt)
  • NCI-2022-01540 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • NRG-GY026 (Annen identifikator: CTEP)
  • NRG-GY026 (Annen identifikator: NRG Oncology)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere